Pharmaceuticals — US PTAB Patent Cases
89 decisions indexed
Page 2 of 3 · 89 total
Encube Ethicals Pvt. Ltd. v.Dermavant Sciences GmbH et al.
Encube Ethicals successfully challenged Dermavant Sciences' patent claims in the PTAB, leading to institution of the case. The Board found sufficient grounds for anticipation (102) and obviousness (103), specifically regarding psoriasis treatment methods. This decision significantly strengthens Encube's position by validating their prior art arguments against the '088 patent.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy's Laboratories challenges Eye Therapies' patent (11833245) in an IPR, arguing all claims are obvious over prior art including Gil and Norden. The petition asserts that the combination of known elements for treating eye redness is motivated by POSA knowledge, favoring institution under Hatch-Waxman principles.
Helena Laboratories Corporation v.Sebia
Helena Laboratories Corporation's IPR challenge against Sebia regarding hemoglobin analysis claims was denied by the PTAB. The Board found that the petitioner failed to demonstrate material error in the Examiner's rejection, particularly concerning prior art references like Shihabi and Huang.
Ovid Therapeutics Inc. v.Marinus Pharmaceuticals, Inc.
Ovid Therapeutics Inc.'s IPR challenge against Marinus Pharmaceuticals, Inc. was denied by the PTAB on grounds of obviousness (103). The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing in its challenges regarding plasma concentration limitations and priority.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully challenged The Johns Hopkins University's patent (11634491) in a PTAB Institution Decision. The Board found reasonable likelihood of success for multiple claims under both anticipation (§ 102) and obviousness (§ 103).
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully challenged The Johns Hopkins University's patent claims regarding MSI-H cancer treatment, leading the PTAB to institute proceedings. The petitioner argued that the claimed methods were anticipated by or obvious over existing prior art, including the MSI-H Study Record and various medical literature.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully petitioned to institute IPR proceedings against The Johns Hopkins University regarding a patent on immunotherapy methods. The Board found reasonable likelihood of unpatentability under both 102 and 103, primarily based on the MSI-H Study Record.
Merck Sharp & Dohme LLC et al. v.The Johns Hopkins University
Merck Sharp & Dohme LLC successfully petitioned to institute IPR against The Johns Hopkins University regarding claims related to anti-PD-1 antibody treatment for MSI colorectal cancer. The Board found a reasonable likelihood of success under both 102 and 103 grounds across all 36 claims at issue.
Alvotech USA Inc. et al. v.Regeneron Pharmaceuticals, Inc.
The PTAB granted institution for the PGR proceeding (PGR2025-00085) involving Alvotech and Regeneron regarding patent 12168036. The petitioner met the likelihood of prevailing standard.
Sarepta Therapeutics, Inc et al. v.The Trustees of the University of Pennsylvania et al.
Sarepta Therapeutics, Inc. successfully challenged several claims of The Trustees of the University of Pennsylvania in an IPR proceeding regarding gene therapy/AAV technology. The Board found a reasonable likelihood of prevailing on multiple grounds of obviousness (35 U.S.C. § 103) using combinations of prior art references.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals
The PTAB granted institution for the PGR proceeding involving Dr. Falk Pharma and Ellodi Pharmaceuticals, allowing the challenge to move forward.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully petitioned to challenge Neurelis, Inc.'s nasal drug formulations patent (8895546) under 35 U.S.C. § 103. The PTAB institution decision allows Padagis to proceed with the unpatentability arguments against all 22 claims.
DR. FALK PHARMA GMBH v.Ellodi Pharmaceuticals LP
DR. FALK PHARMA GMBH challenged Ellodi Pharmaceuticals LP's '729 patent, asserting obviousness of claims related to orally disintegrating corticosteroids for GI tract inflammation. The PTAB declined to deny the petition, finding that additional evidence warranted reconsideration of prior art references like Dohil and FDA Guidance.
Cipla Limited v.Gilead Sciences, Inc.
The PTAB denied Cipla Limited's IPR petition against Gilead Sciences regarding patent 11,744,802, citing the advanced stage of parallel district court litigation and lack of compelling merits.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of Inter Partes Review against Ellodi Pharmaceuticals LP's patent (10632069). The review challenges claims 1-17 based on obviousness over prior art, including Dohil and FDA guidance.
Dr. Falk Pharma GMBH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully petitioned to institute IPR against Ellodi Pharmaceuticals LP's patent (11,246,828) over orally disintegrating tablet claims. The Board found a reasonable likelihood of success based on prior art showing obviousness.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully secured the institution of IPR against Ellodi Pharmaceuticals LP regarding patent 9,486,407. The Board found a reasonable likelihood that prior art (Dohil) renders Claim 35 obvious.
Dr. Falk Pharma GmbH v.Ellodi Pharmaceuticals LP
Dr. Falk Pharma GmbH successfully challenged a pharmaceutical patent (11260061) in an IPR, showing a reasonable likelihood of prevailing on grounds of obviousness (§ 103). The Board's decision hinged on extensive claim construction, particularly defining 'adsorbed onto a pharmaceutically acceptable carrier.'
Samsung Bioepis Co., Ltd. v.Regeneron Pharmaceuticals, Inc.
Samsung Bioepis sought to invalidate numerous claims of Regeneron Pharmaceuticals' ophthalmic formulations using grounds of obviousness (103). The PTAB denied institution based on a holistic Fintiv analysis, citing significant overlap with ongoing district court and MDL proceedings.
Formycon AG v.Regeneron Pharmaceuticals, Inc.
The PTAB denied Formycon AG's IPR against Regeneron Pharmaceuticals, Inc., citing substantial overlap with parallel district court proceedings (MDL). The Board found that the interests of system efficiency were best served by denying institution.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to institute IPR against Seikagaku Corporation's patent (11236318) based on grounds of lack of written description and obviousness. The Board found sufficient evidence at this preliminary stage, allowing the challenge to proceed into full litigation.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully challenged claims 1-18 of Neurelis, Inc.'s patent under grounds of obviousness (103) and lack of written description (102). The Board found a reasonable likelihood that the invention is unpatentable, based on combining prior art references Gwozdz and Meezan.
Padagis US LLC et al. v.Neurelis, Inc.
Padagis US LLC successfully challenged Neurelis, Inc.'s patent claims covering nasal drug delivery formulations. The Board found a reasonable likelihood of prevailing on multiple grounds, leading to the institution of the IPR.
CSPC Pharmaceutical Group Limited et al. v.Ipsen Biopharm Ltd. et al.
The PTAB institution decision in this oncology IPR upheld the patent claims against numerous prior art references related to FOLFIRINOX and nanoliposomal irinotecan. The Board adopted a specific claim construction defining 'treatment' as requiring more than a de minimis therapeutic benefit for the patient.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned the PTAB to institute an IPR against Merus N.V.'s patent (9358286) concerning heterodimeric Ig-like molecules. The Board found sufficient evidence of unpatentability under 35 U.S.C. §§ 102 and 103, advancing the dispute into the substantive review phase.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned to institute IPR against Merus N.V.'s patent (11926859) covering heterodimeric antibodies. The Board found reasonable likelihood of unpatentability based on written description and obviousness grounds.
CSPC Megalith Biopharmaceutical Co., Ltd. et al. v.Shanghai Miracogen Inc. et al.
CSPC Megalith Biopharmaceutical Co., Ltd. successfully argued obviousness over Wei, Liu, and Leanna in an IPR proceeding against Shanghai Miracogen Inc. The Board found a reasonable likelihood of success on multiple claims, leading to the institution of the case for trial.
Valneva Austria GMBH v.Takeda Vaccines, Inc.
Valneva Austria GMBH successfully convinced the PTAB to institute IPR proceedings against Takeda Vaccines regarding a vaccine patent. The Board found a reasonable likelihood that several claims are unpatentable over combinations of prior art, specifically citing evidence related to fetal protection and antibody transfer.
Intas Pharmaceuticals, Ltd. et al. v.Atossa Therapeutics, Inc.
Intas Pharmaceuticals successfully secured the institution of IPR against Atossa Therapeutics over a drug polymorph patent (11,261,151), challenging claims based on anticipation and obviousness using prior art Liu.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.